drugset / Trial / NCT00379574
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
NaSingle-groupOpen-labelTreatment
Summary
Diffuse large B-cell lymphoma is a most prevalent non-Hodgkin's lymphoma. Recently the clinical results have been improved with new drugs and new modalities such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) every 2 weeks. Bortezomib is well known to be effective for multiple myeloma and has been being tried for other malignancies including lymphoma. The investigators will incorporate Bortezomib to CHOP every 2 weeks to further improve the clinical efficacy in diffuse large B-cell lymphoma.
Timeline
- Start
- 2006-09
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Lenograstim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |
| Background | Prednisolone | Other / unclassified | 100 mg | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |